Homelessness at diagnosis is associated with death among people with HIV in a population-based study of a US city.


Journal

AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219

Informations de publication

Date de publication:
01 09 2019
Historique:
pubmed: 2 7 2019
medline: 17 9 2020
entrez: 2 7 2019
Statut: ppublish

Résumé

San Francisco, California, has experienced a 44% reduction in new HIV diagnoses since 2013 supported by its 'Getting to Zero' initiative; however, the age-adjusted mortality rate in people with HIV (PWH) has not decreased. We sought to identify factors associated with death among PWH in San Francisco. Population-based incidence-density case-control study. Among PWH in the San Francisco HIV surveillance registry, a random sample of 48 decedents from 1 July 2016 to 31 May 2017 were each matched to two to three controls who were alive at the date of death (108 controls matched on age and time since diagnosis). Covariates included demographics, substance use, housing status, medical conditions, and care indicators from the study population. We used matched-pair conditional logistic regression to examine factors associated with mortality. Of the 156 PWH in the study, 14% were African-American, 14% Latino, and 8% female sex. In adjusted analysis, factors associated with higher odds of death included: homelessness at HIV diagnosis [adjusted odds ratio (AOR) = 27.4; 95% confidence interval (CI) = 3.0-552.1], prior-year IDU (AOR = 10.2; 95% CI = 1.7-128.5), prior-year tobacco use (AOR = 7.2; 95% CI = 1.7-46.9), being off antiretroviral therapy at any point in the prior year (AOR = 6.8; 95% CI = 1.1-71.4), and being unpartnered vs. married/partnered (AOR = 4.7; 95% CI = 1.3-22.0). People homeless at HIV diagnosis had 27-fold higher odds of death compared with those with housing; substance use and retention on antiretroviral therapy in the prior year are other important intervenable factors. New strategies to address these barriers, and continued investment in supportive housing and substance use treatment, are needed.

Identifiants

pubmed: 31259765
doi: 10.1097/QAD.0000000000002287
pmc: PMC6663574
mid: NIHMS1532843
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1789-1794

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI060530
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069496
Pays : United States

Références

J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):351-8
pubmed: 12131573
Am J Public Health. 2004 Apr;94(4):651-6
pubmed: 15054020
Am J Public Health. 2009 Nov;99 Suppl 3:S675-80
pubmed: 19372524
JAMA. 2009 May 6;301(17):1771-8
pubmed: 19417194
BMC Public Health. 2009 Jul 07;9:220
pubmed: 19583862
Int J Epidemiol. 2009 Dec;38(6):1624-33
pubmed: 19820106
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S22-32
pubmed: 21317590
Clin Infect Dis. 2011 Mar 15;52(6):793-800
pubmed: 21367734
Int J Epidemiol. 2012 Apr;41(2):393-7
pubmed: 22493323
Arch Intern Med. 2012 Jul 23;172(14):1086-95
pubmed: 22711020
Clin Infect Dis. 2014 Sep 1;59(5):725-34
pubmed: 24837481
Clin Infect Dis. 2014 Nov 15;59(10):1471-9
pubmed: 25091306
HIV Med. 2015 Mar;16(3):137-51
pubmed: 25124393
AIDS. 2014 Nov 13;28(17):2573-7
pubmed: 25160935
AIDS Patient Care STDS. 2014 Oct;28(10):517-23
pubmed: 25275657
Eur J Public Health. 2016 Feb;26(1):182-7
pubmed: 25817209
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):348-54
pubmed: 25848927
Am J Public Health. 2015 Oct;105(10):2068-75
pubmed: 26270301
J Health Care Poor Underserved. 2015 Aug;26(3):1005-18
pubmed: 26320929
Drug Alcohol Depend. 2015 Nov 1;156:57-61
pubmed: 26455554
JAMA Psychiatry. 2015 Dec;72(12):1172-81
pubmed: 26509694
Clin Infect Dis. 2016 Oct 15;63(8):1094-1104
pubmed: 27343545
J Infect Dis. 2016 Dec 1;214(11):1672-1681
pubmed: 27815384
Clin Infect Dis. 2018 Mar 19;66(7):1027-1034
pubmed: 29099913
AIDS Behav. 2018 May;22(5):1475-1484
pubmed: 29151199
Cancer Epidemiol. 2018 Feb;52:20-27
pubmed: 29175052
J Acquir Immune Defic Syndr. 2018 May 1;78(1):43-53
pubmed: 29373393
Open Forum Infect Dis. 2018 Mar 14;5(3):ofy035
pubmed: 29577059
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
Front Psychiatry. 2018 Sep 28;9:463
pubmed: 30323773
AIDS Behav. 2019 Mar;23(3):776-783
pubmed: 30684098
JAMA. 2019 Feb 7;:null
pubmed: 30730529
Lancet HIV. 2019 Feb;6(2):e77-e78
pubmed: 30948209
Am J Epidemiol. 1982 Sep;116(3):547-53
pubmed: 7124721

Auteurs

Matthew A Spinelli (MA)

Division of HIV, ID, and Global Medicine.

Nancy A Hessol (NA)

Department of Clinical Pharmacy and of Medicine, University of California, San Francisco.

Sandy Schwarcz (S)

San Francisco Department of Public Health, San Francisco, California, USA.

Ling Hsu (L)

San Francisco Department of Public Health, San Francisco, California, USA.

Maree-Kay Parisi (MK)

San Francisco Department of Public Health, San Francisco, California, USA.

Sharon Pipkin (S)

San Francisco Department of Public Health, San Francisco, California, USA.

Susan Scheer (S)

San Francisco Department of Public Health, San Francisco, California, USA.

Diane Havlir (D)

Division of HIV, ID, and Global Medicine.

Susan P Buchbinder (SP)

San Francisco Department of Public Health, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH